Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ProfoundBio Provides Updates on Two ADC Candidates in US-China Trials

publication date: May 26, 2023

ProfoundBio, a Suzhou-Seattle ADC biotech, has dosed the first patients in a US Phase I/II trial of its CD70 ADC, PRO1160, and it was approved to start a similar trial in China. The company was also approved to start a Phase I/II trial of Rina-S in China. Rina-S, which will be tested in patients with solid tumors or mesothelioma, has already shown promising results in a US trial. Both candidates use ProfoundBio’s novel hydrophilic linker and exatecan payload that is designed to reduce off-target toxicities. More details.....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital